The Apex Times
Above the Noise
Politics Wire
PoliticsSen. John Kennedy demanded answers about whether Jack Smith shared his emails with Attorney General Garland during a Blanche hearingThe Apex TimesPoliticsDemocrats question Jay Clayton over DNI nomination as Section 702 authority lapsesThe Apex TimesPoliticsSen. Bill Cassidy confronts Trump ASPR nominee over alleged misleading hepatitis B vaccine post during confirmation hearingThe Apex TimesPoliticsHuman Rights Campaign backs 29 2026 candidates in battleground districts, spotlighting alignment questions for DemocratsThe Apex TimesPoliticsNYC Bar Association urges Senate to reject acting Attorney General Todd Blanche nominationThe Apex TimesPoliticsSenate Republicans weigh election-integrity language tied to voter ID enforcement as budget reconciliation talks advanceThe Apex TimesPoliticsAOC praises late Sen. Lindsey Graham for backing DEFIANCE Act targeting nonconsensual AI deepfake porn, bill remains stalled in HouseThe Apex TimesPoliticsFCC Chair Brendan Carr says California lawsuit could be dropped if CNN is spun off in Paramount-Warner dealThe Apex TimesPoliticsFed Chairman Kevin Warsh says he speaks with Treasury Secretary Scott Bessent “often,” says Fed independence is protectedThe Apex TimesPoliticsOhio Sen. Jon Husted praises bipartisan housing bill after it became law without President Trump’s signatureThe Apex TimesPoliticsPoll in Michigan Senate primary shows Haley Stevens ahead of Abdul El-Sayed as Sanders and Ocasio-Cortez head to stateThe Apex TimesPoliticsAgriculture Secretary Brooke Rollins tells attendees cyclosporiasis is an FDA responsibility, not a USDA issueThe Apex TimesPoliticsSen. John Kennedy demanded answers about whether Jack Smith shared his emails with Attorney General Garland during a Blanche hearingThe Apex TimesPoliticsDemocrats question Jay Clayton over DNI nomination as Section 702 authority lapsesThe Apex TimesPoliticsSen. Bill Cassidy confronts Trump ASPR nominee over alleged misleading hepatitis B vaccine post during confirmation hearingThe Apex TimesPoliticsHuman Rights Campaign backs 29 2026 candidates in battleground districts, spotlighting alignment questions for DemocratsThe Apex TimesPoliticsNYC Bar Association urges Senate to reject acting Attorney General Todd Blanche nominationThe Apex TimesPoliticsSenate Republicans weigh election-integrity language tied to voter ID enforcement as budget reconciliation talks advanceThe Apex TimesPoliticsAOC praises late Sen. Lindsey Graham for backing DEFIANCE Act targeting nonconsensual AI deepfake porn, bill remains stalled in HouseThe Apex TimesPoliticsFCC Chair Brendan Carr says California lawsuit could be dropped if CNN is spun off in Paramount-Warner dealThe Apex TimesPoliticsFed Chairman Kevin Warsh says he speaks with Treasury Secretary Scott Bessent “often,” says Fed independence is protectedThe Apex TimesPoliticsOhio Sen. Jon Husted praises bipartisan housing bill after it became law without President Trump’s signatureThe Apex TimesPoliticsPoll in Michigan Senate primary shows Haley Stevens ahead of Abdul El-Sayed as Sanders and Ocasio-Cortez head to stateThe Apex TimesPoliticsAgriculture Secretary Brooke Rollins tells attendees cyclosporiasis is an FDA responsibility, not a USDA issueThe Apex TimesPoliticsSen. John Kennedy demanded answers about whether Jack Smith shared his emails with Attorney General Garland during a Blanche hearingThe Apex TimesPoliticsDemocrats question Jay Clayton over DNI nomination as Section 702 authority lapsesThe Apex TimesPoliticsSen. Bill Cassidy confronts Trump ASPR nominee over alleged misleading hepatitis B vaccine post during confirmation hearingThe Apex TimesPoliticsHuman Rights Campaign backs 29 2026 candidates in battleground districts, spotlighting alignment questions for DemocratsThe Apex TimesPoliticsNYC Bar Association urges Senate to reject acting Attorney General Todd Blanche nominationThe Apex TimesPoliticsSenate Republicans weigh election-integrity language tied to voter ID enforcement as budget reconciliation talks advanceThe Apex TimesPoliticsAOC praises late Sen. Lindsey Graham for backing DEFIANCE Act targeting nonconsensual AI deepfake porn, bill remains stalled in HouseThe Apex TimesPoliticsFCC Chair Brendan Carr says California lawsuit could be dropped if CNN is spun off in Paramount-Warner dealThe Apex TimesPoliticsFed Chairman Kevin Warsh says he speaks with Treasury Secretary Scott Bessent “often,” says Fed independence is protectedThe Apex TimesPoliticsOhio Sen. Jon Husted praises bipartisan housing bill after it became law without President Trump’s signatureThe Apex TimesPoliticsPoll in Michigan Senate primary shows Haley Stevens ahead of Abdul El-Sayed as Sanders and Ocasio-Cortez head to stateThe Apex TimesPoliticsAgriculture Secretary Brooke Rollins tells attendees cyclosporiasis is an FDA responsibility, not a USDA issueThe Apex TimesPoliticsSen. John Kennedy demanded answers about whether Jack Smith shared his emails with Attorney General Garland during a Blanche hearingThe Apex TimesPoliticsDemocrats question Jay Clayton over DNI nomination as Section 702 authority lapsesThe Apex TimesPoliticsSen. Bill Cassidy confronts Trump ASPR nominee over alleged misleading hepatitis B vaccine post during confirmation hearingThe Apex TimesPoliticsHuman Rights Campaign backs 29 2026 candidates in battleground districts, spotlighting alignment questions for DemocratsThe Apex TimesPoliticsNYC Bar Association urges Senate to reject acting Attorney General Todd Blanche nominationThe Apex TimesPoliticsSenate Republicans weigh election-integrity language tied to voter ID enforcement as budget reconciliation talks advanceThe Apex TimesPoliticsAOC praises late Sen. Lindsey Graham for backing DEFIANCE Act targeting nonconsensual AI deepfake porn, bill remains stalled in HouseThe Apex TimesPoliticsFCC Chair Brendan Carr says California lawsuit could be dropped if CNN is spun off in Paramount-Warner dealThe Apex TimesPoliticsFed Chairman Kevin Warsh says he speaks with Treasury Secretary Scott Bessent “often,” says Fed independence is protectedThe Apex TimesPoliticsOhio Sen. Jon Husted praises bipartisan housing bill after it became law without President Trump’s signatureThe Apex TimesPoliticsPoll in Michigan Senate primary shows Haley Stevens ahead of Abdul El-Sayed as Sanders and Ocasio-Cortez head to stateThe Apex TimesPoliticsAgriculture Secretary Brooke Rollins tells attendees cyclosporiasis is an FDA responsibility, not a USDA issueThe Apex Times
Back to front
DEA plans temporary Schedule I classification for synthetic kratom compound 7-OH, covering products above set thresholds
The Apex Times

THE APEX TIMES

Politics/The Apex Times/Jul 2, 1:46 PM EDT

DEA plans temporary Schedule I classification for synthetic kratom compound 7-OH, covering products above set thresholds

The Drug Enforcement Administration said it intends to temporarily place 7-hydroxymitragynine (7-OH) and three related synthetic substances into Schedule I, a move aimed at limiting the sale of highly potent kratom-derived products in formats sold online and in convenience stores.

3 min readEditor-approved Apex article

The Drug Enforcement Administration said it plans to temporarily ban products containing the synthetic kratom compound 7-hydroxymitragynine, or 7-OH, by moving it and three related substances into Schedule I under the Controlled Substances Act. The agency said the action is intended to address the spread of chemically modified kratom-related products that, according to the DEA, have risks including tolerance, dependence, and addiction.

DEA on Wednesday outlined the approach, according to news reports, including the two-year duration of the proposed temporary scheduling. The DEA said it could extend the classification for an additional year. Under Schedule I, the Controlled Substances Act category generally reflects a finding of “no accepted medical use” and a high potential for abuse, characteristics the DEA said apply to 7-OH and related chemicals.

The planned ban would apply to products that meet specified concentration or dosage thresholds, including products with 7-OH at or above 0.05% by dry weight, or those with more than 1 milligram of 7-OH. Reporting also said the DEA’s temporary scheduling would cover products sold in formats such as candies, tablets, and liquid “shots,” where 7-OH-related compounds can be marketed as kratom extracts despite containing synthetic opioid-type ingredients.

Alongside 7-OH, the DEA said it intends to temporarily schedule three substances reported as MP, MGM-15, and MGM-16. The DEA said MP does not occur naturally and is a chemical rearrangement product of 7-OH, while MGM-15 and MGM-16 are synthetic derivatives. The agency said these compounds are frequently found online and in products promoted as kratom despite not being naturally present in the plant.

The DEA characterized the compound as presenting severe public health risks, including tolerance, dependence, and addiction, according to the reports describing the agency’s rationale. Shatterproof, a nonprofit focused on addiction policy, was quoted in the same reporting describing the step as long overdue in response to what it characterized as the rapid expansion of potent kratom-related products.

In a statement reported alongside the DEA announcement, Health and Human Services Secretary Robert F. Kennedy Jr. said the scheduling action addressed “highly addictive and harmful substances.” Other reporting described a forthcoming Federal Register step, including that a draft notice of intent would be scheduled for publication the following Monday, setting up the next phase of the temporary scheduling process.

The DEA’s temporary scheduling decision would shift enforcement authority for covered products to federal controlled substance rules, affecting how retailers and online sellers label, distribute, and test inventory that falls above the thresholds. It would also create a new legal compliance baseline for producers and distributors seeking to avoid DEA enforcement by reformulating or removing 7-OH and the designated related substances from products. The practical timeline and ultimate scope would depend on the details in the Federal Register notice and any subsequent DEA action described in the draft.

The reported action sits within a broader pattern of growing federal and state scrutiny of kratom products, with agencies targeting specific synthetic or opioid-like constituents rather than the entire plant in every case. As the DEA moves from its announcement to published notice procedures, regulated parties and enforcement officials would likely focus on product chemistry documentation, quality-control testing, and whether distribution channels carry products that exceed the specified 7-OH concentration or dosage limits.

Why It Matters

  • If implemented as described, the temporary Schedule I move would change federal enforcement for certain kratom-derived products, shifting compliance expectations for sellers and manufacturers.
  • The use of concentration and dosage thresholds suggests enforcement would hinge on product testing and formulation rather than a blanket ban on all kratom goods.
  • Schedule I status would also narrow the legal pathways for marketing and distribution while the DEA pursues further regulatory steps.
  • The timing and details in the forthcoming Federal Register notice could affect how quickly covered products must be removed, reformulated, or ceased from distribution channels.
  • The action illustrates how the federal government is increasingly targeting specific psychoactive compounds within products sold as dietary supplements or herbal alternatives.

Sources

Key Facts

  • The DEA said it plans to temporarily classify 7-OH and three related synthetic substances as Schedule I drugs.
  • The reported schedule would apply for two years, with the possibility of a third-year extension.
  • The reported coverage thresholds include products with 7-OH at or above 0.05% by dry weight, or more than 1 milligram of 7-OH.
  • The DEA identified the three related substances as MP, MGM-15, and MGM-16 and said they do not occur naturally.
  • The reported rationale includes DEA’s stated public health risks, including tolerance, dependence, and addiction.